Overview
Claude Maraoui, President and CEO of Journey Medical, discusses the clinical development program for Emrosi, which was recently approved by the FDA for inflammatory lesions of rosacea in adults.
Clinical Development of Emrosi for Rosacea
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Iris Rubin, MD
David Domzalski
